about
Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British ColumbiaChimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapyFactors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyThe response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
P50
Q37644535-17000AB5-B5E8-456F-9AE2-3C70784CCBA4Q39007364-DD675C89-0D73-40DD-A90D-48C0D58BAA4CQ47682409-5462CBF1-4DF4-4CDD-BF5B-175CC3E71E51Q48021661-B8E4C2B6-D954-408E-8D73-1620FB0A7FFCQ50025150-ACAE99ED-E353-4A73-AB78-B381A8791426Q58577083-6C9343B6-6329-489E-8B67-D4B3C6595159Q91385826-EEA35000-D36D-4BE1-A2C1-79D9175FA4D6Q91723477-19E20D45-A347-49E6-B9EC-6BB3DBE1A953
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Kevin Hay
@en
Kevin Hay
@nl
type
label
Kevin Hay
@en
Kevin Hay
@nl
prefLabel
Kevin Hay
@en
Kevin Hay
@nl
P31
P496
0000-0002-9398-2677